Amendment to the Specification

VW 12/3/10

On page 34, line ~~17~~ 16, please substitute the second full paragraph in application, *i.e.* lines 16-18 with the following:

The proliferation in response to HSV-1 Gp of T lymphocytes from mesenteric lymph node (MLN) ~~MLN~~ and cervical lymph node (CLN) ~~CLN~~ cells of mice immunized ~~immunised~~ with HSV-1 Gp and varying amounts of EtxB is shown in Fig. 3.

VW
12/3/10

Amendments to the Specification

On page 32, replace the 7th paragraph (Page 32, lines 18-20) with the following new paragraphs:

Figure 5A shows the reduction in the incidence of virus shedding in mice immunized with HSV-1/rEtxB.

Figure 5B shows the reduction in the incidence of clinical disease and latency in mice immunized with HSV-1/rEtxB.

VW
12/3/10

On page 33, replace the 10th paragraph (Page 33, lines 35-Page 34 line8 with the following new paragraph (correcting the word "plycoproteins" with "glycoproteins"):

Mice were immunized intranasally three times with 10μg HSV-1 glycoproteins (Gp) with either 10 or 20 μg rEtxB. Controls were either unmanipulated or given a mock preparation of viral glycoprotein (mock) derived from HIV-uninfected tissue culture cells. Antibody levels are expressed as a percentage of post-infection levels. The production of total Ig and IgA in the serum and IgA in eye washings was stimulated by HSV-1 glycoproteins/rEtxB (Figure 1). The present inventors have also shown that doses of rEtxB as low as 0.1 μg are also effective at stimulating such responses.